LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. Small molecule GLP1s?

Small Molecule 139

Small Molecule Trials Therapies Disease 139

PLOS: DNA Science

SEPTEMBER 5, 2024

The most groundbreaking cancer drug approval was for Gleevec , with a mere 3-month trajectory at FDA before its approval in 2001. Gleevec is a small molecule that interferes with entry of an enzyme – a tyrosine kinase – that enables growth signals to enter specific cells and trigger division.

Treatment 52

Treatment FDA Approval DNA Small Molecule 52

Drug Discovery World

APRIL 25, 2023

Dawn Bio which is a drug discovery platform based on human embryo models for drug development for women’s reproductive health. Amplify Therapeutics boasts disease-modifying therapies for Gaucher disease and genetic subgroups of Parkinson’s disease.

Science 130

Science Small Molecule Disease Government 130

Drug Discovery World

AUGUST 5, 2022

Ian Hollingsworth, Associate Director of product development at Boyds, the global drug development consultancy, explains the benefits to the drug development lifecycle of building strong partnerships with external consultants, and when and how to get the best from them. Why sponsors use external consultants.

Drug Development 130

Drug Development Drugs Pharma Companies International 130

Drug Target Review

NOVEMBER 22, 2023

Whilst TGF-β is an attractive target for cancer therapy because of its critical role in promoting tumor aggressiveness, immune escape and resistance to therapy, activation of alternative resistance pathways has hindered drug development attempts in the past.

Licensing 52

Licensing Licensing Small Molecule Therapies 52

The Pharma Data

OCTOBER 18, 2020

DUBLIN–( BUSINESS WIRE )– Inflection Biosciences Ltd , a company developing innovative therapeutics for the treatment of cancer, today announced the appointment of industry veteran Gregory I. Greg possesses a wealth of experience in developing new cancer therapeutics across multiple U.S. Berk, MD, to its Board of Directors.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

NIH Director's Blog: Drug Development

MAY 21, 2020

Just one infusion of this combination antibody therapy lowered the amount of viral genetic material in the animals’ lungs by as much as 30 percent compared to the amount in untreated animals. Meanwhile, there’s been other impressive recent progress towards the development of monoclonal antibody therapies for COVID-19.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

DECEMBER 14, 2020

The effectiveness of standard therapy with TMZ is limited because the response of GBM to TMZ is dependent upon the expression of the DNA repair enzymatic protein, O 6 -alkylguanine DNA alkyltransferase (MGMT). At the stage of GBM relapse and recurrence, no effective therapy strategies currently exist. Contact.

DNA 52

DNA Clinical Trials Drugs Therapies 52

Drug Discovery World

AUGUST 2, 2023

For instance, protein palmitoylation involves the covalent attachment of fatty acyl chains, typically a palmitate to internal cysteine residues of a protein via labile thioester linkages. Ezurpimtrostat (GNS561) was identified from a large library of small molecules as a lead compound for drug development.

Small Molecule 130

Small Molecule Immune Response Clinical Trials International 130

The Pharma Data

DECEMBER 15, 2020

NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Approval demonstrates our ability to execute upon the entirety of the drug development and registration process.

FDA Approval 52

FDA Approval FDA Treatment Small Molecule 52

Agency IQ

APRIL 19, 2024

As the FDA’s Center for Drug Evaluation and Research (CDER) characterized it in a 2023 call for comments : “Evolving understanding of disease biology and molecular pharmacology, advancements in drug discovery, and growth in novel therapeutic platforms (i.e., In particular, regulations in both the U.S.

Clinical Trials 40

Clinical Trials Trials Science FDA 40

Dark Matter Blog

APRIL 8, 2020

And as we’ve launched several internal discovery programs, we are learning the rules of molecular recognition for RNA; yes, the fundamental physical constants are the same, but RNA has mixed them up in fascinating, even wacky, ways; principles that feel hard-wired for protein targets just don’t hold for RNA. We’re lucky.

RNA 52

RNA Small Molecule Synthetic Chemistry Science 52

Drug Discovery World

JANUARY 12, 2023

Oksana Sirenko looks at the advantages and limitations of using organoids from human cell sources in drug development and drug screening. . Altering one base pair can drastically change how the gene’s protein product functions, while mutations can lead to the development of a range of genetic disorders. .

Drugs 246

Drugs Disease Drug Development Therapies 246

Conversations in Drug Development Trends

APRIL 4, 2024

To help integrate these various regulatory standards, the International Council for Harmonization (ICH) of Technical Requirements for Pharmaceuticals for Human Use was founded in 2016. The ICH M10 guidelines aim to streamline this process, reducing redundancy in drug development and facilitating faster access to new therapies.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals International 80

The Pharma Data

AUGUST 29, 2020

Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumab. To date, after at least six months of stable LNP023 add-on therapy, and at the investigators’ discretion, seven patients (70%) have discontinued eculizumab and remained on LNP023 as monotherapy.

Treatment 52

Treatment Disease Small Molecule Production 52

The Pharma Data

OCTOBER 26, 2020

V590 — a SARS-CoV-2 vaccine candidate in development in collaboration with the International AIDS Vaccine Initiative (IAVI) that uses a recombinant vesicular stomatitis virus (rVSV) platform, the same platform used for Merck’s approved Ebola Zaire virus vaccine, will enter Phase 1 development shortly.

Vaccine 40

Vaccine Trials Licensing Licensing 40

Drug Target Review

JULY 7, 2023

There is a clear need for new and approved, safe, effective and innovative targeted therapies to address the underlying causes of autoantibody diseases. The power of precision therapy Targeted — or precision — therapy, a technique that has been honed for many years in cancer treatment, is now being applied in a wider context.

Disease 98

Disease Immune Response Therapies Treatment 98

The Pharma Data

SEPTEMBER 8, 2020

About AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

(LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Cambridge, UK.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

Vial

FEBRUARY 19, 2024

Explore the groundbreaking VersAptx bioconjugation platform, designed to elevate cancer therapies and uncover the delicate balance between clinical excellence and commercial viability in the dynamic landscape of pharmaceuticals. Can you elaborate on how the platform allows your company to tailor therapy? Ahmed Hamdy: Absolutely.

Small Molecule 52

Small Molecule Therapies Treatment Science 52

The Pharma Data

OCTOBER 18, 2020

Separate from the AML trial, Aptose is conducting a Phase 1 a/b dose escalation study with CG-806 in patients with B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphomas (NHL), who have failed or are intolerant to current therapies. About CG-806.

Small Molecule 40

Small Molecule Clinical Trials Trials Therapies 40

New Drug Approvals

SEPTEMBER 13, 2024

4] [6] Aticaprant was originally developed by Eli Lilly , was under development by Cerecor for a time, and is now under development by Janssen Pharmaceuticals. [2] 12] Positron emission tomography imaging revealed that brain KORs were almost completely saturated by the drug 2.5 Drug Discovery. nM vs. 24.0

Treatment 62

Treatment Pharmacokinetics Clinical Trials Pharmaceuticals 62

Agency IQ

APRIL 19, 2024

Patients frequently receive up to four therapies at once and go through multiple prolonged courses of treatment to keep recurrence and progression at bay. Commonly combined treatment options include antineoplastics (chemotherapies), radiation therapy, corticosteroids, immunomodulators, proteasome inhibitors, and monoclonal antibodies.

FDA 40

FDA Disease Trials Clinical Trials 40

Agency IQ

DECEMBER 11, 2023

FDA also convened seven Oncologic Drugs Advisory Committee (ODAC) meetings in 2023, offering a candid window into the application review process and the internal deliberations of reviewers grappling to strike a balance between timely access of patients to new products while upholding the rigor of FDA review.

FDA 40

FDA Science Clinical Trials Trials 40

The Pharma Data

DECEMBER 27, 2020

As part of its broad development program, BeiGene expects to work with the NHSA for potential NRDL inclusion in future expanded indications for these medicines. As part of its broad development program, BeiGene expects to work with the NHSA for potential NRDL inclusion in future expanded indications for these medicines.

Production 52

Production Therapies Treatment Drugs 52